Efficacy and Safety of Biweekly Regimen of Eribulin Versus a Standard Regimen for the Treatment of Locally Recurrent or Metastatic HER2-negative Breast Cancer: a Multicenter, Randomized, Open-label, Phase III Trial

NCT06857305 · clinicaltrials.gov ↗

PHASE3

Phase

ENROLLING_BY_INVITATION

Status

192

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer Metastatic

Interventions

DRUG: Eribulin biweekly regimen
DRUG: Eribulin standard regimen

Sponsor

Ma Fei，MD